SonoScape Medical (300633) Fundamentals 2026 — P/E 47.0x, Revenue Analysis | SniperIQ
SonoScape Medical (300633) is a CN-listed Healthcare company in Medical - Devices with a market capitalization of ¥8.2B, trading at ¥19.36 on the SHZ. This SniperIQ fundamentals page covers SonoScape Medical's valuation (P/E 47.0x, P/B 2.6x), profitability (net margin 7.5%), revenue (¥2.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is SonoScape Medical's market cap?
SonoScape Medical (300633) has a market capitalization of approximately ¥8.2B, trading at ¥19.36 on the SHZ. Market cap moves with the live share price.
What is SonoScape Medical's P/E ratio?
SonoScape Medical's trailing twelve-month P/E ratio is 47.0x, with a price-to-book (P/B) of 2.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is SonoScape Medical?
SonoScape Medical runs a net profit margin of 7.5%, a gross margin of 61.1%, and an operating margin of 5.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does SonoScape Medical generate?
SonoScape Medical reported revenue of ¥2.3B for fiscal year 2025, with net income of ¥197M and earnings per share (EPS) of 0.46. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does SonoScape Medical pay a dividend?
SonoScape Medical offers a trailing dividend yield of about 0.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is SonoScape Medical financially healthy?
SonoScape Medical carries a debt-to-equity ratio of 0.08x and a current ratio of 2.96x, with a market beta of -0.37. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is SonoScape Medical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For SonoScape Medical (300633) the key facts are: market cap ¥8.2B, P/E 47.0x, revenue ¥2.3B, 52-week range 17.2-37.73. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track SonoScape Medical's full fundamentals live
Get SonoScape Medical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.